{
  "consolidation_metadata": {
    "timestamp": "2025-10-01T13:55:19.535200",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "picos",
    "data_split": "test",
    "total_consolidated_picos": 87,
    "source_countries": [
      "AT",
      "BE",
      "CZ",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_picos": [
    {
      "Population": "adults with HCC in Barcelona Clinic Liver Cancer (BCLC) stage B or C who did not receive any prior systemic therapy for the advanced or inoperable disease. Hepatic cirrhosis of any aetiology was not an exclusion criterion. Patients in BCLC stage B had to be ineligible for transarterial chemoembolization (TACE). Further inclusion criteria were Child-Pugh stage A and an Eastern Cooperative Oncology Group – Performance Status (ECOG-PS) score of 0 or 1.",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "adults with HCC in Barcelona Clinic Liver Cancer (BCLC) stage B or C who did not receive any prior systemic therapy for the advanced or inoperable disease. Hepatic cirrhosis of any aetiology was not an exclusion criterion. Patients in BCLC stage B had to be ineligible for transarterial chemoembolization (TACE). Further inclusion criteria were Child-Pugh stage A and an Eastern Cooperative Oncology Group – Performance Status (ECOG-PS) score of 0 or 1.",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "Child-Pugh A patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "Child-Pugh A patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "Child-Pugh A patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "placebo",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "Child-Pugh A patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "placebo"
      }
    },
    {
      "Population": "hepatocellular carcinoma patients",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "placebo",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "hepatocellular carcinoma patients",
        "intervention": "Medicine X (under assessment)",
        "comparator": "placebo"
      }
    },
    {
      "Population": "patients with advanced HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "TACE",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "patients with advanced HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "TACE"
      }
    },
    {
      "Population": "patients with advanced HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "TACE + sorafenib",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "patients with advanced HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "TACE + sorafenib"
      }
    },
    {
      "Population": "patients with advanced HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "arterial embolization",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "arterial embolization"
      }
    },
    {
      "Population": "treatment naive adult (aged ≥18 years) patients with advanced, unresectable or metastatic hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "treatment naive adult (aged ≥18 years) patients with advanced, unresectable or metastatic hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "Adult patients with advanced HCC and adult patients with inoperable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "Adult patients with advanced HCC and adult patients with inoperable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "DK",
        "ES",
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 3,
      "Grouping_Key": {
        "population": "patients with unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "adults with advanced or unresectable HCC who have not had previous systemic treatment, with Child-Pugh grade A liver impairment and an ECOG performance status of 0 or 1",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "EN"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adults with advanced or unresectable HCC who have not had previous systemic treatment, with Child-Pugh grade A liver impairment and an ECOG performance status of 0 or 1",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "adults with advanced or unresectable HCC who have not had previous systemic treatment, with Child-Pugh grade A liver impairment and an ECOG performance status of 0 or 1",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "EN"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adults with advanced or unresectable HCC who have not had previous systemic treatment, with Child-Pugh grade A liver impairment and an ECOG performance status of 0 or 1",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "patients with unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "ES"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "patients with unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "placebo",
      "Countries": [
        "ES"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "placebo"
      }
    },
    {
      "Population": "adult patients with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "ES"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma (HCC) (stage BCLC B or C) who have not received prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma (HCC) (stage BCLC B or C) who have not received prior systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma and preserved hepatic function (Child Pugh stage A)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma and preserved hepatic function (Child Pugh stage A)",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma and preserved general condition (ECOG ≤ 2) and preserved hepatic function (Child-Pugh A)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma and preserved general condition (ECOG ≤ 2) and preserved hepatic function (Child-Pugh A)",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced hepatocellular carcinoma who had not been previously systemically treated and were not (anymore) eligible for surgical or locoregional treatment, such as surgery, irradiation, (haemoglobin) embolization",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "placebo",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced hepatocellular carcinoma who had not been previously systemically treated and were not (anymore) eligible for surgical or locoregional treatment, such as surgery, irradiation, (haemoglobin) embolization",
        "intervention": "Medicine X (under assessment)",
        "comparator": "placebo"
      }
    },
    {
      "Population": "patients with hepatocellular carcinoma in whom initiation of curative treatment or (continuation) of locoregional or local palliative treatment is not possible or considered medically inappropriate",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "best care regimen available",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with hepatocellular carcinoma in whom initiation of curative treatment or (continuation) of locoregional or local palliative treatment is not possible or considered medically inappropriate",
        "intervention": "Medicine X (under assessment)",
        "comparator": "best care regimen available"
      }
    },
    {
      "Population": "adult patients with advanced or non-resectable hepatocellular carcinoma (HCC) and who have not received any previous systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced or non-resectable hepatocellular carcinoma (HCC) and who have not received any previous systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "adult patients with advanced or non-resettable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Tecentriq (atezolizumab) plus bevacizumab",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced or non-resettable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "Tecentriq (atezolizumab) plus bevacizumab"
      }
    },
    {
      "Population": "adult patients with advanced or non-resettable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced or non-resettable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "adult patients with advanced or non-resettable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Lenvima (lenvatinib)",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced or non-resettable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "Lenvima (lenvatinib)"
      }
    },
    {
      "Population": "patients with HCC with non-viral etiologies",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Tecentriq plus bevacizumab",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with HCC with non-viral etiologies",
        "intervention": "Medicine X (under assessment)",
        "comparator": "Tecentriq plus bevacizumab"
      }
    },
    {
      "Population": "patients for whom treatment with atezoumab plus bevacizumab is inappropriate",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients for whom treatment with atezoumab plus bevacizumab is inappropriate",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "patients for whom treatment with atezoumab plus bevacizumab is inappropriate",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients for whom treatment with atezoumab plus bevacizumab is inappropriate",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab and bevacizumab",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "atezolizumab and bevacizumab"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "durvalumab with tremelimumab",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "durvalumab with tremelimumab"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "AT",
        "DE",
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 3,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "AT",
        "DE",
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 3,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma who have not received durvalumab in the first line",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pembrolizumab",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma who have not received durvalumab in the first line",
        "intervention": "Medicine X (under assessment)",
        "comparator": "pembrolizumab"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "best supportive care",
      "Countries": [
        "AT",
        "DE",
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 3,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "best supportive care"
      }
    },
    {
      "Population": "patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "arterial chemoembolization",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "arterial chemoembolization"
      }
    },
    {
      "Population": "patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "radioactive Iodine 131 treatment",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "radioactive Iodine 131 treatment"
      }
    },
    {
      "Population": "patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "systemic chemotherapy (doxorubicin or cisplatin)",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "systemic chemotherapy (doxorubicin or cisplatin)"
      }
    },
    {
      "Population": "patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "hormonal therapy with tamoxifen",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "hormonal therapy with tamoxifen"
      }
    },
    {
      "Population": "patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "subcutaneous octreotide therapy",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "subcutaneous octreotide therapy"
      }
    },
    {
      "Population": "patients treated with SIRT",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients treated with SIRT",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child–Pugh class A",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "BSC",
      "Countries": [
        "ES"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child–Pugh class A",
        "intervention": "Medicine X (under assessment)",
        "comparator": "BSC"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab plus bevacizumab",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "atezolizumab plus bevacizumab"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma who progressed on sorafenib treatment",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "regorafenib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma who progressed on sorafenib treatment",
        "intervention": "Medicine X (under assessment)",
        "comparator": "regorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma who progressed on sorafenib treatment",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "cabozantinib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma who progressed on sorafenib treatment",
        "intervention": "Medicine X (under assessment)",
        "comparator": "cabozantinib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma and increased alpha-fetoprotein concentrations following first-line sorafenib",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "ramucirumab",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma and increased alpha-fetoprotein concentrations following first-line sorafenib",
        "intervention": "Medicine X (under assessment)",
        "comparator": "ramucirumab"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma previously treated with sorafenib",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "nivolumab plus ipilimumab",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma previously treated with sorafenib",
        "intervention": "Medicine X (under assessment)",
        "comparator": "nivolumab plus ipilimumab"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "transarterial chemoembolization (TACE)",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "transarterial chemoembolization (TACE)"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "selective internal radiation therapy (SIRT)",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "selective internal radiation therapy (SIRT)"
      }
    },
    {
      "Population": "patients with advanced HCC, who have failed or are not eligible for local-regional therapy, with impaired hepatic function (Child-Pugh B)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "IT"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced HCC, who have failed or are not eligible for local-regional therapy, with impaired hepatic function (Child-Pugh B)",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced and/or unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "FOLFOX4",
      "Countries": [
        "IT"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced and/or unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "FOLFOX4"
      }
    },
    {
      "Population": "patients with advanced and/or unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "doxorubicin",
      "Countries": [
        "IT"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced and/or unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "doxorubicin"
      }
    },
    {
      "Population": "patients with advanced hepatocellular carcinoma who had not received previous systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced hepatocellular carcinoma who had not received previous systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced hepatocellular carcinoma who had not received previous systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab with bevacizumab",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced hepatocellular carcinoma who had not received previous systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "atezolizumab with bevacizumab"
      }
    },
    {
      "Population": "patients with advanced hepatocellular carcinoma who had not received previous systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced hepatocellular carcinoma who had not received previous systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "regorafenib",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "regorafenib"
      }
    },
    {
      "Population": "patients with non-surgical hepatocellular carcinoma in good general condition and with good liver function (Child and Pugha Class A)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "combination of bevacizumab and atezolizumab",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with non-surgical hepatocellular carcinoma in good general condition and with good liver function (Child and Pugha Class A)",
        "intervention": "Medicine X (under assessment)",
        "comparator": "combination of bevacizumab and atezolizumab"
      }
    },
    {
      "Population": "patients previously treated with Sorafenib with AFP ≥ 400 ng/ ml",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "ramucyrumab",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients previously treated with Sorafenib with AFP ≥ 400 ng/ ml",
        "intervention": "Medicine X (under assessment)",
        "comparator": "ramucyrumab"
      }
    },
    {
      "Population": "patients who are well tolerant of sorafenib",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "regorafenib",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients who are well tolerant of sorafenib",
        "intervention": "Medicine X (under assessment)",
        "comparator": "regorafenib"
      }
    },
    {
      "Population": "second-line patients who have previously received bevacizumab with atezolizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "second-line patients who have previously received bevacizumab with atezolizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "second-line patients who have previously received bevacizumab with atezolizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "leninivat",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "second-line patients who have previously received bevacizumab with atezolizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "leninivat"
      }
    },
    {
      "Population": "second-line patients who have previously received bevacizumab with atezolizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "cabozantinib",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "second-line patients who have previously received bevacizumab with atezolizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "cabozantinib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab and bevacizumab",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A)",
        "intervention": "Medicine X (under assessment)",
        "comparator": "atezolizumab and bevacizumab"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) when combination therapy is inappropriate",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "tremelimumab-durvalumab combination",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) when combination therapy is inappropriate",
        "intervention": "Medicine X (under assessment)",
        "comparator": "tremelimumab-durvalumab combination"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma following the progress of first line treatment with TKI",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "regorafenib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma following the progress of first line treatment with TKI",
        "intervention": "Medicine X (under assessment)",
        "comparator": "regorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma following the progress of first line treatment with TKI",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "cabozantinib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma following the progress of first line treatment with TKI",
        "intervention": "Medicine X (under assessment)",
        "comparator": "cabozantinib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma following the progress of first line treatment with TKI",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "ramucirumab",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma following the progress of first line treatment with TKI",
        "intervention": "Medicine X (under assessment)",
        "comparator": "ramucirumab"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "regorafenib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "regorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "cabozantinib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "cabozantinib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "ramucirumab",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "ramucirumab"
      }
    }
  ]
}